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Abstract
Malaria control efforts have been continuously stymied by drug-resistant strains of Plasmo-
dium falciparum, which typically originate in Southeast Asia prior to spreading into high-
transmission settings in Africa. One earlier proposed explanation for Southeast Asia being
a hotbed of resistance has been the hypermutability or “Accelerated Resistance to Multiple
Drugs” (ARMD) phenotype, whereby multidrug-resistant Southeast Asian parasites were
reported to exhibit 1,000-fold higher rates of resistance to unrelated antimalarial agents
when compared to drug-sensitive parasites. However, three recent studies do not recapitu-
late this hypermutability phenotype. Intriguingly, genome sequencing of recently derived
multidrug-resistant Cambodian isolates has identified a high proportion of DNA repair gene
mutations in multidrug-resistant parasites, suggesting their potential role in shaping local
parasite evolution. By adapting fluctuation assays for use in P. falciparum, we have exam-
ined the in vitromutation rates of five recent Cambodian isolates and three reference labo-
ratory strains. For these studies we also generated a knockout parasite line lacking the
DNA repair factor Exonuclease I. In these assays, parasites were typed for their ability to
acquire resistance to KAE609, currently in advanced clinical trials, yielding 13 novel muta-
tions in the Na+/H+-ATPase PfATP4, the primary resistance determinant. We observed no
evidence of hypermutability. Instead, we found evidence of a mild mutator (up to a 3.4-fold
increase in mutation rate) phenotype in two artemisinin-resistant Cambodian isolates,
which carry DNA repair gene mutations. We observed that one such mutation in the Mis-
match Repair protein Mlh1 contributes to the mild mutator phenotype when modeled in
yeast (scmlh1-P157S). Compared to basal rates of mutation, a mild mutator phenotype
may provide a greater overall benefit for parasites in Southeast Asia in terms of generating
drug resistance without incurring detrimental fitness costs.
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Introduction
Malaria infections caused by the eukaryotic pathogen Plasmodium falciparum place an
immense burden on many under-resourced nations around the world, particularly in sub-
Saharan Africa. Over the past 15 years, considerable progress towards reducing the global bur-
den of malaria has been achieved through the widespread adoption of highly effective artemisi-
nin-based combination therapies (ACTs) and mosquito control [1]. These gains, however, are
threatened by the emergence of ACT resistance in Western Cambodia [2], which has now
spread across Southeast Asia [3].
The emergence of artemisinin resistance in Southeast Asia recalls that of resistance to earlier
first-line antimalarials, notably chloroquine (CQ) and sulfadoxine-pyrimethamine [4–7]. CQ
resistance spread from Southeast Asia to the far higher endemicity regions of Africa in the
1980s, where CQ resistance still persists [5]. It was earlier hypothesized that CQ-resistant
Southeast Asian strains exhibited a hypermutability phenotype compared to non-Southeast
Asian counterparts [8, 9], enabling the former to acquire single nucleotide polymorphisms
(SNPs) and new drug resistance traits at an accelerated rate.
Evidence supporting this hypermutability phenotype, termed “Accelerated Resistance to
Multiple Drugs” (ARMD), came from resistance selection studies with the antimalarial com-
pounds 5-fluoroorotic acid (5-FOA) and atovaquone. Those data reported that the Southeast
Asian multidrug-resistant W2 strain was much more mutable (by 10 to 1,000-fold) as com-
pared to non-Southeast Asian strains [8]. However, detailed analyses of the mutation rates of
the W2 strain or its clone Dd2, propagated in long-term in vitro culture, in comparison with
reference strains, have since shown no evidence in favor of an ARMD phenotype [10, 11]. Fur-
thermore, in silico analysis of contemporary P. falciparum genomes fromMali and Southeast
Asia also found no evidence of an ARMD phenotype [12].
These studies provide compelling evidence that the ARMD phenotype is not characteristic
of Southeast Asian multidrug-resistant parasites. Nevertheless, recent whole-genome sequenc-
ing of Asian and African patient-derived isolates (obtained between 2007 and 2011) has
revealed mutations in a number of DNA repair genes that are overrepresented in parasites
from Cambodia, where artemisinin resistance first emerged [9]. These mutations occurred pri-
marily in the Mismatch Repair (MMR) factors Mlh1, Pms1, and Exo1. In bacteria found in nat-
ural environments, such as the human gastrointestinal system, mild mutator strains encoding
MMRmutations have been shown to account for a larger percentage of total cells (25%) com-
pared to hypermutators (1%), and the former associate with a higher degree of antibiotic resis-
tance [13–15]. Furthermore, mild mutators can acquire drug resistance that requires multiple
SNPs more efficiently than hypermutators [16]. Long-term in vitro propagation has shown
that bacterial hypermutators frequently display fitness costs associated with the accumulation
of detrimental mutations, whereas mild mutators provide sufficient genetic diversity with min-
imal fitness costs [17, 18].
Based on these observations, we hypothesized that Cambodian isolates encoding mutations
in DNA repair genes could drive a mild mutator phenotype. To investigate this possibility, we
have adapted a fluctuation assay for P. falciparum using the spiroindolone compound KAE609
[3, 19], which scores for resistance-conferring SNPs in pfatp4 and enables the comparison of
mutation rates for a diverse collection of parasite strains. Using this method, we observed two
artemisinin-resistant Cambodian isolates that exhibit a mild mutator phenotype and 13 novel,
resistance-conferring mutations in pfatp4. By modeling the MMR gene mutation (pfmlh1-
P203S) in yeast, we observed that this alone can drive a mild mutator phenotype.
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Materials and Methods
Parasites
Laboratory strains (3D7, W2, Dd2, and V1/S) were obtained from the Malaria Research and
Reference Reagent Resource Center (MR4). All Cambodian clones (PH0167-C, PH0164-C,
PH0306-C, PH0482-C, and PH0212-C) were isolated by Dr. Rick Fairhurst (NIAID/NIH) in
Pursat, western Cambodia in 2010 [20, 21]. The Exonuclease I-deficient Dd2 exo1Δ line was
generated from Dd2, as described below. A description of parasite origins is provided in S1
Table.
Parasite culturing and DNA analysis
Asexual blood stage parasites were maintained in human red blood cells in RPMI-1640 malaria
culture media containing 0.5% (w/v) Albumax II (Invitrogen) under 5% O2, 5% CO2, 90% N2
as described [22].
Parasite trophozoite-infected erythrocytes were harvested and saponin-lysed. Parasite geno-
mic DNA (gDNA) was extracted and purified with QIAGEN DNeasy Blood Kits. KAE609-
resistant gDNA was extracted, and pfatp4 (PF3D7_1211900) was amplified by PCR using
primers 5’-GTAGAAGAATCACCTAAATCTATAGG-3’ and 5’-CAAGCAAAATTTTTACCA
CATG-3’. PCR products were Sanger sequenced.
Construction of the P. falciparum exo1Δmutant
To generate a P. falciparum exo1Δ knockout strain, we generated the pcamBSD-exo1 plasmid
that was used to genetically disrupt the pfexo1 (PF3D7_0725000) open reading frame. First, a
1187 bp fragment of pfexo1 encoding NotI and PstI restriction sites was PCR amplified from
Dd2 gDNA using primers 5’-CTTGCGGCCGCGTAATGATTTTCATATAACTGGTATGGG-3’
and 5’-CTTCTGCAGCATCGAAAGTATGTTCACACGTTCCG-3’. This NotI and PstI digested
fragment was cloned into pcamBSD [23], which encodes the blasticidin-S-deaminase (bsd)
selectable marker, yielding pcamBSD-exo1. Dd2 parasites were transfected with purified circu-
lar pcamBSD-exo1 plasmid as described [22]. One day post-electroporation, parasites were
exposed to 2 μg/ml of blasticidin (Invitrogen). Blasticidin media was replaced daily until day 7
post-electroporation and every 2 days thereafter. Transformed parasites were detected by light
microscopy 11 days post-electroporation, maintained in blasticidin-containing media, and
periodically checked by PCR for single site crossover-based plasmid integration into the pfexo1
locus. This PCR screen used the primers 5’-TCACTAAAGGGAACAAAAGCTGG-3’ and
5’-AAGGTCATCCTTCTTTTCCCAC-3’. Plasmid integration was detected on day 31 post-
electroporation. The mixed culture was then cloned by limiting dilution in a 96-well plate [24].
To detect clones, plates were screened by flow cytometry on an Accuri C6 flow cytometer cou-
pled to a HyperCyt autosampler, with infected red blood cells (iRBCs) labeled using 1.6 μM
Mito Tracker Deep Red and 2× SYBR Green (Invitrogen) [25]. Integration-positive clones
were confirmed by PCR.
KAE609 fluctuation assays
For a schematic representation of the fluctuation assay, see Fig 1A. On day 0, each parental par-
asite strain was first cloned by limiting dilution. Single clones were expanded to ~5×108 total
iRBCs and then seeded into two 96-well plates. Stocks were also cryopreserved at this time. The
first plate was inoculated with 2.5×108 total iRBCs of a parental clone at ~3% hematocrit in
selective media containing 2.5 nM KAE609 (kindly provided by Dr. Thierry Diagana, Novartis
Institute of Tropical Diseases) [19]. The second plate (0.8 parasites/well) was a control in
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which a parental clone was cloned again by limiting dilution in a 96-well plate (without drug
pressure) to calculate an accurate starting culture density (number of iRBCs/ml).
KAE609-containing selective media (with 0.9% hematocrit) was added to drug-pressured
96-well plates daily for 4 days, followed by the addition of fresh selective media (without RBCs)
every 48 hours. Fresh RBCs were added on days 14, 17, and 20. Drug-resistant clones were
detectable by flow cytometry generally around day 20 post-inoculation (matching the growth
rate for unpressured clones).
Fluctuation assay mutation rate calculation
Mutation rates were calculated for both parasite and yeast fluctuation assays using the Ma-
Sandri-Sarkar Maximum Likelihood Estimator (MSS-MLE) Method via the online Fluctuation
Analysis Calculator (FALCOR) [26]. In this analysis, r is the total count of KAE609-resistant
clones per parental clone tested, and Nt is the corrected starting number of parasites deter-
mined from each clone’s control plate. MSS-MLE is considered to be a more accurate method
of calculating mutation rates as compared to the Lea-Coulson or other methods [27]. Statistical
analysis was performed using Prism 6 (GraphPad Software, Inc.).
In vitro susceptibility assays
In vitro IC50 values were measured by incubating parasites for 72 hours across a range of
KAE609 concentrations (0.2–100 nM). Final parasitemia were measured by flow cytometry
and IC50 values were calculated by non-linear regression analysis [25].
Fig 1. Determination of mutation rates in a KAE609 fluctuation assay. (A) Schematic of fluctuation assay protocol. (B) KAE609 fluctuation assay
mutation rates (light blue bars and bolded text) calculated by MSS-MLE for n independent clones. Two-tailed Student’s t-tests were performed for each strain
relative to 3D7 with the exception of Dd2 exo1Δ, which was compared to Dd2, its isogenic background parent (#). 95% confidence intervals (lower and upper
limits) are denoted in brackets. Fold changes (fc) are listed relative to 3D7. Dd2 exo1Δ is compared to Dd2. * p = 0.02, ** p < 0.01.
doi:10.1371/journal.pone.0154166.g001
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Yeast plasmid and strain construction
Themlh1Δ strain SJR0538 (MATa ade2-101oc his3Δ200 ura3ΔNco lys2ΔBgl mlh1Δ::URA3) has
been previously reported [28]. This strain was transformed by heat shock with three separate
plasmids, namely pEAA213 [29], pEAA213-P157S, and pEAA213-K30A-E31A. pEAA213
encodes the full-length S288cMLH1 gene inserted in pRS415 (ARSH4 CEN6 LEU2 KANMX).
TheMLH1 gene in pEAA213 was mutated by site-directed mutagenesis to generate the
mlh1-P157S andmlh1-K30A-E31A expressing plasmids pEAA213-P157S and pEAA213--
K30A-E31A, respectively. These transformations yielded SJR0538-WT, SJR0538-P157S, and
SJR0538-K30A-E31A.
Yeast media and growth conditions
SJR0538-WT, SJR0538-P157S, and SJR0538-K30A-E31A were all grown in YEP medium (1%
yeast extract, 2% Bacto Peptone; 2.5% agar for plates) supplemented with 2% glycerol and 2%
ethanol (YEPGE) and 200 μg/ml G418 (Geneticin). Synthetic complete (SC) medium contain-
ing 2% dextrose and lacking lysine (SC-Lys) was used for selective growth.
lys2ΔBgl fluctuation assays
All yeast strains were propagated for three days on YEPD+G418 plates. Single clones were
inoculated in 10 ml of YEPGE+G418 liquid medium and propagated for 2 days at 30°C with
constant shaking. Cells were harvested by centrifugation, washed once with ddH2O, and resus-
pended in 1 ml of ddH2O. Dilutions were plated onto SC-Lys plates for 3 days at 30°C to select
for Lys+ revertants, or control YEPD plates to calculate an accurate starting inoculum. Nine
clones were tested for SJR0538-WT and SJR0538-P157S, and eleven for SJR0538-K30A-E31A.
Results and Discussion
Some Cambodian isolates exhibit a mild mutator phenotype
To determine mutation rates for a diverse selection of P. falciparum strains, we adapted the
fluctuation assay, a common microbiological method to measure and compare mutation rates
[30–32], to P. falciparum. Fluctuation assays estimate mutation rates based on the distribution
of mutant clones that arise in parallel cultures subjected to selective pressure.
In our P. falciparum-adapted fluctuation assay (Fig 1), we pressured parasites with the spir-
oindolone compound KAE609 (also known as NITD609 or cipargamin) [33]. We chose
KAE609 for three major reasons: (1) Resistance to low-level (2.5 nM) KAE609 can be readily
conferred by a number of unique SNPs in pfatp4 [19, 34–36]. Given more than one indepen-
dent SNP in pfatp4 can yield resistant clones, we were therefore able to capture a broad range
of mutation rates, including for low or basal rates (e.g. that of the drug-sensitive reference 3D7
strain). In the original ARMD report, only one of five strains pressured with 5-FOA yielded a
frequency of resistance measurement [8]. (2) Using KAE609 is much less time and resource
intensive than using drugs that select for resistance at much lower frequencies (3). KAE609 is
also fast acting [37]. Mutations that impart resistance would therefore have to be present at the
time of drug exposure in order for parasites to survive. This speed of action was preferred to
slower acting agents that might allow resistance-conferring SNPs to be encoded beyond the
first generation of selective pressure, which would yield inflated mutation rates.
In our KAE609 fluctuation assays (Fig 1), we assayed 3D7, W2, and Dd2, which have been
shown to have similar basal mutation rates [10, 11], and therefore served as wild-type controls.
As a benchmark for a mild mutator phenotype, we generated and assayed a P. falciparum Exo-
nuclease I knockout strain (Dd2 exo1Δ). exo1Δ strains exhibit mild mutator phenotypes in
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other organisms, as Exonuclease I often mediates the fastest, although non-essential, mecha-
nism for many DNA repair pathways [30, 38]. We also tested V1/S, a multidrug-resistant Viet-
namese strain [39, 40] that carries two DNA repair gene mutations (Table 1) found in
contemporary artemisinin-resistant Cambodian isolates, suggesting that it too may exhibit a
mild mutator phenotype. Finally, we tested five recently derived Cambodian isolates that
encode various DNA repair mutations [9]. These isolates were chosen to encompass the poten-
tial contributions of DNA repair mutations in Cambodian isolates. For instance, PH0167-C is
artemisinin-sensitive and encodes no mutations overrepresented in artemisinin-resistant iso-
lates (Table 1). PH0167-C nonetheless harbors two unique DNA repair gene mutations, not
associated with artemisinin resistance. In contrast, PH0212-C encodes four mutations associ-
ated with artemisinin resistance, in particular for the two factors Mlh1 and Pms1 that are both
essential for MMR.
Parallel cultures of each strain were pressured and maintained in 2.5 nM KAE609 in 96-well
plates until resistant clones were detectable by flow cytometry (See Materials and Methods).
To confirm that our fluctuation assays yielded KAE609-resistant clones, we determined half-
maximal inhibitory concentration (IC50) values using 72 hour in vitro susceptibility assays for
each parent and two randomly selected drug-pressured clones. Sanger sequencing of the pfatp4
gene from resistant clones yielded 16 total mutations, 13 of which have not been previously
reported (Table 2).
As mentioned above, the polymorphic nature of pfatp4 in response to KAE609 allowed us
to calculate mutation rates for all strains, including wild-type strains, which was previously not
possible for 5-FOA [8]. It is important to note that these mutation rates are specific to
KAE609, for which resistance in vitro can be mediated by single SNPs, and are useful for calcu-
lating relative differences between strains. However, the absolute KAE609 mutation rates
should not be directly compared with those calculated using other drugs or methods of calcula-
tion unless the studies are conducted in parallel. As examples, selection for mefloquine resis-
tance typically results in pfmdr1 gene amplification [41], for chloroquine multiple mutations in
pfcrt are required [42], and for atovaquone mutations involve single SNPs in the genome of
mitochondria, which are present as multiple copies per parasite [43].
With all strains, mutation rates were compared to 3D7, except for Dd2 exo1Δ that was com-
pared to its parental Dd2 strain. These data revealed no significant differences between 3D7,
W2, and Dd2 in their KAE609 mutation rates. This result was not consistent with the original
ARMD study, which reported that W2 was hypermutable relative to 3D7 [8]. We also observed
no significant differences in mutation rates amongst the three Cambodian isolates PH0167-C,
PH0306-C, and PH0164-C that carried fewer DNA repair gene mutations compared to the two
other isolates (Table 1, Fig 1B). These observations provide additional evidence against an
ARMD phenotype being present in the W2 strain.
Results with our Dd2 exo1Δ line showed a statistically significant 2.5-fold increase in muta-
tion rate relative to its isogenic background parent Dd2. This is similar to yeast exo1Δ strains,
which exhibit a 3-fold increase in mutation rate in lys2ΔBgl fluctuation assays [44], and con-
firms the usefulness of Dd2 exo1Δ as a benchmark mild mutator in P. falciparum fluctuation
assays.
We observed mild mutator phenotypes in three additional strains. V1/S exhibited a non-
statistically significant 1.7-fold increase in mutation rate relative to 3D7. However, its mutation
rate was very similar to Dd2 exo1Δ. PH0482-C and PH0212-C exhibited statistically significant
2.3- and 3.4-fold increases relative to 3D7, respectively (Fig 1B). As stated above, PH0482-C
and PH0212-C encode the most DNA repair gene mutations that cluster with artemisinin
resistance. These data suggest some correlation between DNA repair gene mutations and the
mild mutator phenotype, which merits further investigation.
Evidence of a Mild Mutator Phenotype in Cambodian Malaria Parasites





































































































































































































































































































































































































































































































































































































































































































































































































































































Evidence of a Mild Mutator Phenotype in Cambodian Malaria Parasites
PLOS ONE | DOI:10.1371/journal.pone.0154166 April 21, 2016 7 / 14
Our data also yielded useful insights into KAE609. As stated above, we observed 13 novel
pfatp4mutations in KAE609-resistant clones (S1 Fig). Prior studies using KAE609 or other
PfATP4 inhibitors have to date reported 24 mutations in this gene [19, 35, 36, 45, 46]. The
polymorphic nature of pfatp4 in response to low drug concentrations exemplifies its ideal use
for fluctuation analyses in P. falciparum. In vitro KAE609 susceptibility experiments, however,
cannot recapitulate the pharmacokinetic and pharmacodynamic properties of this compound
in vivo. Indeed, efficacy studies in humans will be required to assess the parasitological and
clinical risk associated with the polymorphic nature of pfatp4. Pharmacokinetic studies in
Table 2. pfatp4mutations and IC50 values for parasites used in KAE609 fluctuation assay.
Strain Clone Pressured Mutations IC50 ± SEM (nM)
e Fold Changef p valuef
3D7 B2 No WT 0.79 ± 0.01 1.0 −
B3 Yes S312P 3.61 ± 0.47 4.6 0.01
E6 Yes T416N 8.00 ± 0.18 10.2 0.0003
W2a D2 No WT 0.78 ± 0.06 1.0 −
H6 Yes V414D 3.52 ± 0.09 4.5 0.0009
E12 Yes S312P 2.78 ± 0.22 3.6 0.003
Dd2a A7 No WT 0.58 ± 0.10 1.0 −
D9 Yes Q172Hb 3.52 ± 0.14 6.1 0.001
Dd2 exo1Δa C11 No WT 0.49 ± 0.05 1.0 −
D7 Yes I379N 2.88 ± 0.27 5.8 0.006
E2 Yes I379N 2.70 ± 0.26 5.5 0.006
V1/Sa B6 No WT 1.10 ± 0.13 1.0 −
B2 Yes V204L/L350Vc 7.34 ± 0.22 6.7 0.001
E4 Yes L938I 4.27 ± 0.23 3.9 0.003
PH0167-Ca A2 No WT 0.41 ± 0.03 1.0 −
D9 Yes Q172Hb 4.66 ± 0.59 11.4 0.01
PH0306-Ca A3 No WT 0.60 ± 0.07 1.0 −
D6 Yes V400A 5.42 ± 0.32 2.5 0.003
B9 Yes A421E 1.51 ± 0.13 9.0 0.02
PH0164-C E8 No WT 0.55 ± 0.03 1.0 −
D1 Yes P966Ad 4.06 ± 0.22 7.4 0.002
F1 Yes E895K 1.91 ± 0.17 3.5 0.006
PH0482-Ca F4 No WT 0.98 ± 0.11 1.0 −
C1 Yes A1207V 2.17 ± 0.07 2.2 0.006
A6 Yes A1158V 1.63 ± 0.13 1.7 0.002
PH0212-Ca G2 No WT 0.73 ± 0.09 1.0 −
A6 Yes A1158V 3.50 ± 0.17 4.8 0.003
A1 Yes A967G 24.3 ± 0.76 33.4 0.0005
B12 Yes A967G 20.9 ± 2.23 28.7 0.006
D3 Yes L350Hc 15.2 ± 2.58 21.0 0.01
C7 Yes V400A 9.61 ± 0.32 13.2 0.0004
a Harbors the additional pfatp4 polymorphism G1128R.
b Previously observed in [36], pressured with MMV007275.
c Previously observed in [35], pressured with (+)-SJ733.
d Previously observed in [35], pressured with KAE609.
e n = 3 independent assays in duplicate for each IC50 value.
f Relative to isogenic parent. p values were determined using the Student’s t test. WT = wild-type.
doi:10.1371/journal.pone.0154166.t002
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humans show that a 300 mg dose of KAE609 can produce a maximum plasma concentration
of around 2 μg/ml in 3 to 8 hours [47]. This equates to roughly 5 μMKAE609, which is
2,000-fold higher than the 2.5 nM concentration used in our drug pressure experiments. Also,
the largest changes in IC50 values attributed to single or double mutations in response to 2.5
nM KAE609 so far have been only 20 to 30–fold ([19] and Table 2).
The Cambodian mutant Mlh1 allele exhibits a minor mutator phenotype
in yeast
We sought to model the DNA repair gene mutations found in artemisinin-resistant parasites
in a yeast system to test for a possible association between these mutations and mutator pheno-
types. Among these mutations, only one gene, the MMR factor Mlh1, had a mutation (pfmlh1-
P203S) that could be mapped to a yeast ortholog [48], in this case Mlh1 (scmlh1-P157S) (Fig
2A). The ability to map the Mlh1 mutation is serendipitous for a number of reasons. First,
Mlh1 is an essential MMR protein that plays a major role in the generation of SNPs [18, 49].
Second, the pfmlh1-P203S mutation is found in the mild mutator P. falciparum strains
PH0212-C and PH0482-C. Third, the homologous residue in yeast, scmlh1-P157, is located in
a conserved region near motif IV of the essential N-terminal ATPase domain (Fig 2A). Fourth,
in yeast the mutation to lysine at residue P157 produces a strong mutator phenotype in an
exo1Δ background, which amplifies the mutator effect [30]. A mutation at the homologous res-
idue in human MLH1 has also been associated with hereditary nonpolyposis colorectal cancer
[50], a cancer mediated by mutations in MMR genes. Finally, among the 3,000 P. falciparum
isolates sequenced in the Pf3k database, the pfmlh1-P203S mutation has only been found in
Fig 2. Determination of mutation rates for a clinically relevantmlh1 allele in yeast. (A) Schematic of the yeast Mlh1 (ScMlh1) amino acid sequence.
Yellow domains represent the N-terminal region containing the GHL superfamily ATPase, ATPase motifs, and the essential residues K30 and E31. The
ScMlh1-P157 (and homologous PfMlh1-P203) residue is denoted in the conserved N-terminal domain. Blue domains representing the conserved C-terminal
domain are also shown. “Dimerization” domains are important for dimerization with Pms1. The “Regulatory” region is important for Mlh1 regulation. The MIP
binding sites are important for interactions with factors such as Exo1 [48]. (B) Yeast lys2ΔBgl fluctuation assay mutation rates (yellow bars and bolded text)
comparing wild-type (WT), scmlh1-P157S, and scmlh1-K30A E31A. Two-tailed Student’s t-test compared to wild-type. 95% confidence intervals (lower and
upper limits) are denoted in brackets. Fold changes (fc) are listed relative to scmlh1-WT. *** p < 0.0001.
doi:10.1371/journal.pone.0154166.g002
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Southeast Asia (in Cambodia, Myanmar, Thailand, and Vietnam), and never in Africa or Ban-
gladesh [51].
To test the effect of scmlh1-P157S, we transformed a Mlh1 knockout yeast strain (SJR0538:
lys2ΔBgl mlh1Δ) with plasmids encoding either wild-type scmlh1-WT, or scmlh1-P157S, or
scmlh1-K30A E31A. In yeast, scmlh1-WT was shown to fully rescue MMR functionality,
whereas the ATPase-dead scmlh1-K30A E31A plasmid phenocopied a full Mlh1 knockout
[52]. To test for mutability differences, each yeast strain also encoded an internal frameshift in
LYS2 (lys2ΔBgl), which rendered the strain auxotrophic for lysine. Reversion to lysine prototro-
phy requires a return to wild-type functionality, but not necessarily wild-type sequence, as a
number of different reversion events in lys2ΔBgl can restore function. Therefore, the lys2ΔBgl
fluctuation assay measures an artificially increased mutation rate [28], similar in concept to
our KAE609 assay, as in both assays several distinct genetic changes can produce the selected
phenotype. For each of the three scmlh1 strains, we measured mutation rates by measuring the
return to growth on media lacking lysine (Fig 2B).
Our wild-type and K30A E31A strains provided the lower and upper limits of our assay,
respectively. K30A E31A had a mutation rate of 5.29×10−7 mutations per generation (95% con-
fidence intervals (CI) [4.4×10−7, 6.2×10−7], n = 11), which was 23.3-fold higher (p<0.0001,
two-tailed Student’s t-test) than the wild-type, whose rate was calculated at 0.23×10−7 (95% CI
[0.14×10−7, 0.33×10−7], n = 9). Our scmlh1 P157S strain exhibited an elevated mutation rate of
0.37×10−7 (95% CI [0.24×10−7, 0.52×10−7], n = 9), a 1.6-fold increase compared to wild-type
(p<0.0001, two-tailed Student’s t-test). These data provide evidence that the scmlh1-P157S
mutation can confer a mild mutator phenotype.
Given the conservation of the region in which it lies, themlh1-P203S mutation in P. falcipa-
rum likely also mediates a mild mutator phenotype, particularly if compounded with additional
DNA repair mutations (e.g. Pms1). Gene editing experiments are currently ongoing to examine
the contributions of MMRmutations to mild mutator phenotypes in P. falciparum.
In our study, we have focused on the effects of DNA repair gene mutations in the intraery-
throcytic, asexual cycle. It is tempting to consider that the effects of these mutations might also
extend to the sexual stages that genetically recombine in the Anophelesmosquito host. In meio-
sis, for instance, the complex of Mlh1-Mlh3 (MutLγ) and Exo1 has been shown to resolve mei-
otic crossovers [53]. Additionally, the Mlh1-Pms1 complex (MutLα) prevents post-meiotic
segregation and divergence from Mendelian inheritance [54]. We posit that P. falciparum
DNA repair mutations might reduce meiotic recombination and thereby contribute to the
maintenance of multigenic drug-resistant traits in Southeast Asian strains. Such a mechanism
would be consistent with the over-representation of these DNA repair genes in artemisinin-
resistant parasites in Cambodia, which comprise genetically distinct parasite subpopulations
whose primary resistance determinant K13 appears to be in linkage disequilibrium with multi-
ple genetic traits on distinct chromosomes [9]. Dissecting the role of these DNA repair genes in
meiosis will require the investigation of rates of chromosomal crossovers in gene-edited P. fal-
ciparum parasites examined in Anophelesmosquitoes, a complex but exciting undertaking.
Since the ARMD phenotype was initially described [8], examining whether this is a consis-
tent characteristic of multidrug-resistant parasites has focused on finding hypermutators with
very large variations in mutability rates compared to drug-sensitive parasites. Studies in natural
bacterial populations present an alternative perspective. Hypermutator strains can and do
acquire resistance to drugs quickly in vitro, but when propagated longer become outcompeted
by mild mutators due to an accumulation of additional detrimental mutations [17, 18]. Mild
mutators can more readily provide an appropriate balance between the ability to adapt to drug
pressure via the acquisition of resistance-conferring mutations and the need to maintain over-
all fitness [14, 16, 18]. This may have been important for the acquisition of resistance to earlier
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first-line antimalarial therapies such as CQ or pyrimethamine+sulfadoxine, or current first-
line artemisinin-based therapies, which require multiple mutations in one or more genes to
build full resistance [6, 42, 55]. Further research will be necessary to determine to what extent a
mild mutator phenotype in P. falciparum facilitates the acquisition of multidrug resistance in
parasite populations, as has been observed in bacteria.
Conclusion
We provide evidence of a mild mutator phenotype in some contemporary Cambodian isolates,
using a fluctuation assay adapted for use in P. falciparum. These strains are artemisinin-resis-
tant and carry multiple DNA repair gene mutations. One such mutation, pfmlh1-P203S, drives
a mild mutator phenotype when modeled in yeast. In describing this phenotype, we provide
further evidence that the ARMD phenotype cannot be recapitulated, under the drug selection
conditions adopted herein. As such, we posit that the focus in P. falciparum should be shifted
from the ARMD phenotype to a more detailed examination of mild mutator phenotypes,
which have been shown to be more relevant than hypermutators for antibiotic resistance and
evolution of natural bacterial populations [13–16].
Supporting Information
S1 Fig. pfatp4mutations that confer resistance to KAE609. (A) Amino acid changes in
PfATP4 determined from KAE609-resistant parasites in our study (denoted in red) and
PfATP4 mutations from previously published studies. Previously reported mutations were
identified when pressuring parasites with a GNF-Pf4492 [45], b MMV011567 [36], c
MMV007275 [36], d C2-1 [46], e KAE609 [19], f NITD678 [19], g KAE609 [35], h SJ733 [35], i
SJ311 [35], j NITD678 [35], or k MMV772 [35]. l The variant residue G1128R was found in
some parental lines not pressured with KAE609 and was also reported in [36]. PfATP4
domains were determined using the Pfam database of protein families, version 28.0 [56]. (B) A
PfATP4 homology model (C-score: -1.68, estimated TM-score 0.51±0.15, estimated RMSD
13.7±4.0Å) showing the 3D locations of the mutations found in this study (red spheres).
Homology modeling was performed via the I-TASSER online server [57, 58] and visualized
with Protean 3D (DNASTAR Lasergene version 12) and Adobe Illustrator CS4.
(PDF)
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